Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 29, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - July 29, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/29/14 - A*STAR partners Roche to develop new cancer therapeutics
By a News Reporter-Staff News Editor at China Weekly News Singapore-A* STAR's Bioprocessing Technology Institute has entered into an agreement with one of the world's largest pharmaceutical company, Roche, to identify novel drug candidates for the detection and treatment of cancer. The partnership brings together BTI's capabilities in novel antib
7/29/14 - Arena Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., July 29 Arena Pharmaceuticals, San Diego, has been assigned a patent developed by 11 co-inventors for "3- phenyl-pyrazole derivatives as modulators of the 5- HT2A serotonin receptor useful for the treatment of disorders related thereto." The co-inventors are Bradley Teegarden, San Diego, Yifeng Xiong, San Diego, Sonja Strah-Pleyn
7/29/14 - BioAlliance Pharma Partner Innocutis Introduces Sitavig in U.S. [Professional Services Close - Up]
BioAlliance Pharma noted that herpes labialis is an extremely widespread condition. "The U.S. launch of Sitavig, a drug from the R&D of BioAlliance Pharma, confirms once more our know-how in the development and registration of products in the U.S. We are very confident in Innocutis' sales team commitment and know-how to successfully implement the
7/29/14 - Biomarin Pharmaceutical Assigned Patent
ALEXANDRIA, Va., July 29 Biomarin Pharmaceutical, Novato, California, has been assigned a patent developed by two co-inventors for "formulations for lysosomal enzymes." The co-inventors are Jonathan LeBowitz, Novato, California, and Byeong Chang, Sherman Oaks, California. Written by Eloisa Asedillo; edited by Vessie Ann Abalos.
7/29/14 - Boston Scientific Gets FDA Approval for REBEL Platinum Chromium Coronary Stent System [Manufacturing Close - Up]
Boston Scientific has received FDA approval for the REBEL Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease. The REBEL Stent System expands the Boston Scientific family of stents featuring its proprietary platinum chromium alloy and a customized stent architecture.
7/29/14 - China to put Glaxo investigators on trial Aug. 8
BEIJING A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial." Yu and Humphrey worked for Gla
7/29/14 - CORRECTION: Mapi Pharma postpones and halves Nasdaq IPO [Globes, Tel Aviv, Israel :: ]
July 28 Jul. 28 The Globes issued a correction to the story headlined " Mapi Pharma postpones and halves Nasdaq IPO", sent by McClatchy-Tribune Regional News on July 28. Mapi Pharma postpones and halves Nasdaq IPO. Drug developer Mapi Pharma, which was scheduled to complete a $37 million financing round at the end of last week, published a revi
7/29/14 - County raises incentives offer to drug maker [The Herald-Sun, Durham, N.C. :: ]
July 29 DURHAM County Commissioners have raised their business-incentive offer to a Durham- based pharmaceutical company that's developing new treatments for kidney cancer, HIV and lupus. Deputy County Manager Marqueta Welton voiced confidence Monday that the increased offer will produce into a decision by Argos to remain in Durham.
7/29/14 - Erytech Pharma Highlights Study of ERY-ASP in Acute Lymphoblastic Leukemia [Professional Services Close - Up]
Erytech Pharma reported the enrollment of the first patient in its Phase I/II study with ERY-ASP in Acute Lymphoblastic Leukemia in the United States of America. The study has been authorized by the FDA in 2013 and three centers are currently open for patient recruitment: The University of Chicago, Duke University Medical Center and Ohio State Univ
7/29/14 - Findings on Biochemical Parasitology Detailed by Investigators at University of Strathclyde (ES-62, a therapeutic anti-inflammatory agent evolved by...
Findings on Biochemical Parasitology Detailed by Investigators at University of Strathclyde. By a News Reporter-Staff News Editor at Life Science Weekly Investigators publish new report on Life Science Research. Our news journalists obtained a quote from the research from the University of Strathclyde, "It is well known that parasitic worms modul
7/29/14 - Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer
Glide Pharmaceutical Technologies Ltd today announced that it has taken an exclusive worldwide licence to an innovative prostate cancer diagnostic technology from FScan Ltd, a Durham University spin-out company. Further clinical validation of this approach is currently underway in studies co-ordinated by Professor Mark Emberton, Consultant...
7/29/14 - IFPMA supports World Hepatitis Day 2014
Release date- 28072014- On the occasion of World Hepatitis Day, the International Federation of Pharmaceutical Manufacturers and Associations calls for collaboration to increase awareness on and understanding of a disease which silently kills still many. The World Health Assembly approved last May a resolution on Hepatitis asking for the developmen
7/29/14 - Iroko Pharmaceuticals: Calox De Costa Rica to Market and Sell Zorvolex in Latin America [Professional Services Close - Up]
Iroko Pharmaceuticals reported that its affiliate, Iroko Pharmaceuticals Inc., signed a licensing agreement with Calox De Costa Rica S.A. for the rights to market and sell Zorvolex capsules in specified countries in Latin America. In a release, the Company noted Calox will be responsible for obtaining regulatory and pricing approval, as well as the
7/29/14 - J&J -IMBRUVICA (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p
Release date- 28072014- HORSHAM, PA,- The U.S. Food and Drug Administration has approved the supplemental New Drug Application for IMBRUVICA capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. IMBRUVICA is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacycli
7/29/14 - Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA for use in the Treatment of Two Forms of Blood Cancer
Release date- 25072014- Beerse/ Belgium- Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA in the European Union. Ibrutinib is being co-developed by Janssen and...
7/29/14 - KaloBios Regains Global Rights To KB001-A From Sanofi Pasteur
PARIS- KaloBios Pharmaceuticals, Inc. said Monday that it has reached an agreement with Sanofi Pasteur, the vaccines division of Sanofi, to regain all rights to KaloBios' KB001-A program. Sanofi Pasteur agreed to terminate the collaboration and licensing agreement with KaloBios in consideration of low single digit royalties on net sales of KB001-A,
7/29/14 - KaloBios Regains Global Rights To KB001-A, Ends Deal With Sanofi Pasteur
PARIS- Shares of KaloBios Pharmaceuticals, Inc. tumbled almost 12 percent in extended trades Monday after the company said that Sanofi Pasteur has agreed to terminate their collaboration and licensing agreement and handed the full global rights to the KB001-A development program back to the company. Sanofi Pasteur is the vaccines division of French
7/29/14 - Medicines360 and Actavis Secures FDA Acceptance for Filing of NDA for Levosert IUD [Manufacturing Close - Up]
Medicines360 and Actavis reported that the U.S. Food and Drug Administration has accepted for filing Medicines360's New Drug Application for Levosert, a hormonal intrauterine contraceptive for use by women to prevent pregnancy. According to a media release, in June 2013, Medicines360 and Actavis announced that they had entered into a partnership th
7/29/14 - New Chlamydia and Gonorrhea Assays on the BD Viper LT System Receive FDA 510k Clearance
Release date- 28072014- Baltimore, MD- BD Diagnostics, a segment of BD, announced today it has received 510 clearance from the U.S. Food and Drug Administration for the BD ProbeTec Chlamydia trachomatis Qx Amplified DNA Assay and the BD ProbeTec Neisseria gonorrhoeae Qx Amplified DNA Assay on the BD Viper LT System. 'The BD Viper LT System and BD P
7/29/14 - Panmira Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., July 29 Panmira Pharmaceuticals, San Diego, has been assigned a patent developed by three co-inventors for "ophthalmic pharmaceutical compositions of DP2 receptor antagonists." The co-inventors are John Howard Hutchinson, San Diego, Thomas Jon Seiders, San Diego, and Nicholas Simon Stock, San Diego. Written by Eloisa Asedillo; ed
7/29/14 - Penn Pharma to be sold to PCI in a Pounds 127m deal [Western Mail (Wales)]
Penn Pharmaceuticals, which employs around 300 people in Wales, is a global provider of specialist pharmaceutical services headquartered in Tredegar. The company provides selected Contract Development and Manufacturing Organisation services to a global customer base to support the outsourcing needs of international customers including those in...
7/29/14 - Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com
This Latest Guidebook for Conducting Pharma Clinical Trials in China: From Regulations to Practice not only provided a comprehensive and thorough knowledge of the latest Chinese regulations on clinical trials for imported drug registration but also introduced the practical operation how to comply with the Chinese GCP to guide you to use the Chinese
7/29/14 - Quark Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., July 29 Quark Pharmaceuticals, Fremont, California, has been assigned a patent developed by two co-inventors for compositions and methods "for reducing or protecting against delayed graft function." The co-inventors are Shai Erlich, Belmont, California, and Elena Feinstein, Rehovot, Israel. Written by Eloisa Asedillo; edited by V
7/29/14 - Research and Markets Adds Report: US Pharmaceutical Companies Contacts Directory [Health & Beauty Close - Up]
Research and Markets has announced the addition of the "US Pharmaceutical Companies Contacts Directory" directory to its offerings. In a release, Research and Markets noted that report highlights include:. This is a directory of 2,658 companies in the US Pharmaceutical industry.
7/29/14 - Researchers Submit Patent Application, "Herbal Compositions for the Treatment of Mucosal Lesions", for Approval
By a News Reporter-Staff News Editor at Life Science Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors LEVINE, William Z.; SAFFER, Aron J.; FRAN, Mina, filed on March 12, 2014, was made available online on July 17, 2014. The patent's assignee is Izun Pharmaceuticals Corporation. News editors obtain
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415